Global circulating tumor cells (CTCs) market is anticipated to grow at a CAGR of 12.5% during the forecast period (2023-2030). An increase in the adoption of CTC detection, including non–invasive techniques used for the detection of cancer is driving industry growth. This technique includes the use of body fluids and their analysis for the determination of cancerous and circulating tumor cells in the patient body. The complex nature of tumors and their heterogenicity, result in a rise in research and development for inventing new techniques, resulting in the growth of the circulating tumor cell market. It is widely accepted that the capture, enumeration, and identification of circulating tumor cells (CTCs) hold significant promise for early cancer screening, diagnosis, and prognosis. According to the National Institute of Health (NIH), in July 2020, The advent of new diagnostic and treatment modalities improved the 5-year relative survival rate for all types of cancers combined the survival rate increased substantially from 39.0% to 70.0% among white patients and from 27.0% up to 63.0% among black patients.
Browse the full report description of “Circulating Tumor Cells Market Size, Share & Trends Analysis Report By Technology (CTC Detection and Enrichment Methods, CTC Direct Detection Methods, and CTC Analysis), By Product (Kits and Reagents, Blood Collection Tubes and Devices), and By End Users (Hospitals and Clinics, Research and Academic Institutes and Diagnostic Centers), Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/circulating-tumor-cells-market
Researchers can analyze and characterize enriched CTCs from a molecular perspective with a high level of specificity, gaining valuable insights into how certain tumors progress and disseminate throughout the body. For instance, in February 2021, Menarini-Silicon Biosystems in liquid biopsy and single-cell technologies, launched its innovative CellMag product line for the manual enrichment and staining of rare circulating tumor cells (CTCs). This new product line, composed of the CellMag CTC Epithelial Cell kit, a magnetic tool, and consumables, will allow all liquid biopsy and CTC laboratories to have access to a manual system using the same ferrofluid technology offered by the Gold Standard CELLSEARCH system.
Several new kits capture CTCs from cancers originating in epithelial cells, known as carcinomas. Carcinomas include leading cancer types, such as cancers of the breast, lung, colon, prostate, and bladder. The development of better tools and applications for researchers and clinicians revolutionizing cancer diagnosis through liquid biopsy is also fueling market growth. For instance, in September 2023, nRichDX® launched its new RUO-labeled CTC enrichment kit that uniquely isolates Circulating Tumor Cells (CTCs) from up to 40mL of whole blood samples to help researchers advance liquid biopsy assay research and development.
Various platforms are designed to scan, analyze, and digitally image up to 2 million cells per slide, based on multiple biomarker combinations. In November 2021, Ikonisys Inc. Launched the next generation of CTC Detection and analysis platforms to expand its US presence. The company plans to use the funds to accelerate its commercial development in both the US and Europe and for working capital, with approximately 20.0% of the financing going toward further research and development. Ikoniscope20 is the newest version of the company's Ikoniscope platform, a fully automated workflow for the automation of fluorescent in situ hybridization assays, and the detection, isolation, and analysis of rare cells, with applications in circulating tumor cell (CTC)-based testing and personalized medicine.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Technology
o By Product
o By End Users
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- Bio-Rad Laboratories, Inc., Illumina, Inc., Johnson & Johnson, QIAGEN N.V., Thermo Fisher Scientific Inc., and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Circulating Tumor Cells Market Report Segment
By Technology
By Product
By End Users
Global Circulating Tumor Cells Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/circulating-tumor-cells-market